Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-08-04
1999-12-28
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514212, 514422, A61K 3140, A61K 31445, A61K 3155
Patent
active
060082321
ABSTRACT:
A method of preventing headache in a human is disclosed which comprises the administration to a human in need thereof of an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.3 are, independently, --H, --CH.sub.3, --CO(C.sub.1 -C.sub.6 alkyl), or --COAr, where Ar is optionally substituted phenyl;
R.sup.2 is selected from the group consisting of pyrrolidine, piperidine, and hexamethyleneimino; or
a pharmaceutically acceptable salt or solvate thereof.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5075321 (1991-12-01), Schreiber
patent: 5389670 (1995-02-01), Fontana
patent: 5391557 (1995-02-01), Cullinan et al.
patent: 5441947 (1995-08-01), Dodge et al.
patent: 5462950 (1995-10-01), Fontana
patent: 5482949 (1996-01-01), Black et al.
patent: 5484808 (1996-01-01), Grinnell
patent: 5492927 (1996-02-01), Gitter et al.
patent: 5504094 (1996-04-01), Bruns, Jr. et al.
patent: 5521198 (1996-05-01), Zuckerman
patent: 5534526 (1996-07-01), Cullinan
patent: 5545641 (1996-08-01), Bruns, Jr. et al.
patent: 5670523 (1997-09-01), Brandi et al.
Draper et al., "Effects of Raloxifene (LY139481 HCl) on Biochemical Markers of Bone and Lipid Metabolism Healthy Postmemopausal Women", Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.
Evans et al., "Raloxifene is a Tissue Specific Estrogen Agonist", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolik et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am. Soc. Bone & Min. Res., Tampa Sep. 18-22, 1993.
Glasebrook et al., "Multiple Binding Sites for the Antiestrogen Raloxifene", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., "Raloxifene and Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TCGB-3 Expression in Bone;" Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;" The Endocrine Society, Abstract 1982.
Black et al., "Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice," Life Sciences, 26:1980, 1453-1458.
Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., "Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms," Endocrinology 109; 1981, 987-989.
Black, L.J. "Biological Actions and Binding Properites of a New Estrogen Antagonist LY117018," In: Hormone Antagosists, 129-82, 1982, (M.K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.
Black, et al., LY156758: A Unique Antiestrogen Displaying High Affinity Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93.
Black et al., Antagonism of Estrogen Action with a New Benzothiophene Derived Antiestrogen, Life Sciences, 32:1983, 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Jones et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2 (4-methoxyphenyl-1-naphthalenyl] [4-[2-pyrrolidinyl) ethoxyl]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22:1979, 962-966.
Jones et al., Antiestrogens 2, Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b] thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med.Chem. 27(8), 1984, 1057-166.
Dodge et al., Abstract to EP 747376A1, 1996.
Bryant, et al., Raloxifene (LY139481 HCI): Bone, Lipid And Uterine Effects in the Ovariectomized Rat Model J. Bone & Min. Res., vol. 8, Supp. 1, No. 26, (1993).
Black, et al., "Raloxifene (LY139481 HCI) Prevents Bone Loss and Reduces Serum Cholesterol Without Causing Uterine Hypertrophy in Ovariectomized Rates". J. Clin. Invest., vol. 93, 63-69 (1994).
Boudreaux William R.
Eli Lilly and Company
Sales James J.
Spivack Phyllis G.
LandOfFree
Methods for preventing headaches does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preventing headaches, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preventing headaches will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2382691